Suppr超能文献

[高钾血症——当前的治疗策略]

[Hyperkalemia - current therapuetic strategies].

作者信息

Głogowski Tomasz, Wojtaszek Ewa

机构信息

Katedra i Klinika Nefrologii, Dializoterapii i Chorób Wewnętrznych WUM, Warszawa, Polska,

Katedra i Klinika Nefrologii, Dializoterapii i Chorób Wewnętrznych WUM, Warszawa, Polska.

出版信息

Wiad Lek. 2016;69(5):745-748.

Abstract

Hyperkalemia is a medical emergency that requires immediate therapy, followed by interventions aimed at preventing its recurrence. Hyperkalemia occurs especially frequently in patients with chronic kidney disease (CKD), in part because of impaired kidney function and in part due to coexisting comorbidities such as diabetes or heart failure and the medications used to treat them, first of all the inhibitors of renin-angiotensin-aldosterone system (RAASi). Both acute and chronic management of hyperkalemia are equally important, though, with currently available therapeutic possibilities, the effective restoration of potassium homeostasis are in fact limited to the correction of its triggers. The emergence of new medications (patiromer and ZS-9) could lead to a therapeutic paradigm shift from intermittent treatment of incidentally discovered hyperkalemia toward preventive measures preventing fluctuations in serum potassium levels and enabling the continuation of beneficial, but hyperkalemia inducing agents.

摘要

高钾血症是一种需要立即治疗的医疗急症,随后需采取措施预防其复发。高钾血症在慢性肾脏病(CKD)患者中尤为常见,部分原因是肾功能受损,部分原因是并存的合并症,如糖尿病或心力衰竭以及用于治疗这些疾病的药物,首先是肾素 - 血管紧张素 - 醛固酮系统抑制剂(RAASi)。不过,高钾血症的急性和慢性管理同样重要,尽管有目前可用的治疗方法,但实际上有效恢复钾稳态仅限于纠正其触发因素。新药物(帕替罗姆和ZS - 9)的出现可能导致治疗模式从偶然发现的高钾血症的间歇性治疗转向预防血清钾水平波动并允许继续使用有益但会诱发高钾血症的药物的预防措施。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验